Outcomes of liver and cardiovascular metabolic diseases among lean vs non-lean individuals with metabolic dysfunction-associated steatotic liver disease

Figure 1 Research flowchart.

Figure 2 Summary of risk-of-bias assessments using Risk of Bias in Non-randomized Studies-of Exposure tool.

Figure 3 Liver fibrosis in lean vs non-lean metabolic dysfunction-associated steatotic liver disease. MASLD: Metabolic dysfunction-associated steatotic liver disease; CI: Confidence interval.

Figure 4 Metabolic dysfunction-associated steatohepatitis in lean vs non-lean metabolic dysfunction-associated steatotic liver disease. MASH: Metabolic dysfunction-associated steatohepatitis; MASLD: Metabolic dysfunction-associated steatotic liver disease; CI: Confidence interval.

Figure 5 Steatosis in lean vs non-lean metabolic dysfunction-associated steatotic liver disease. MASLD: Metabolic dysfunction-associated steatotic liver disease; CI: Confidence interval.

Figure 6 Cirrhosis in lean vs non-lean metabolic dysfunction-associated steatotic liver disease. MASLD: Metabolic dysfunction-associated steatotic liver disease; CI: Confidence interval.

Figure 7 Cardiovascular disease in lean vs non-lean metabolic dysfunction-associated steatotic liver disease. CVD: Cardiovascular disease; MASLD: Metabolic dysfunction-associated steatotic liver disease; CI: Confidence interval.

Figure 8 Hypertension in lean vs non-lean metabolic dysfunction-associated steatotic liver disease. HTN: Hypertension; MASLD: Metabolic dysfunction-associated steatotic liver disease; CI: Confidence interval.

Figure 9 Mortality in lean vs non-lean metabolic dysfunction-associated steatotic liver disease. MASLD: Metabolic dysfunction-associated steatotic liver disease; CI: Confidence interval.